Key result
The 2006 guidelines state that enoxaparin with tenecteplase is the most comprehensively studied therapy for acute coronary syndrome patients under 75 without significant renal dysfunction.
No takes yet. Share an insight, caveat, or question.
The 2006 ACS guidelines recommend enoxaparin in combination with tenecteplase for patients under 75 years of age without significant renal dysfunction.
Little et al. (2007) conducted a letter in acute coronary syndromes. Enoxaparin in conjunction with tenecteplase was evaluated. The 2006 guidelines state that enoxaparin with tenecteplase is the most comprehensively studied therapy for acute coronary syndrome patients under 75 without significant renal dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: